Air Liquide supplies oxygen and equipment to temporary hospitals built for patients affected by COVID-19 in Ontario

Air Liquide crew unloads liquid oxygen in the supply system recently installed at the Trillium Health Partners temporary hospital in Mississauga.

In response to needs driven by the COVID-19 pandemic, Air Liquide teams in Canada have quickly mobilized to equip temporary hospitals built to support and treat COVID-19 patients in Ontario. In April, Air Liquide, in collaboration with local hospitals, contractors and engineers, helped open three temporary hospitals in Ontario: Joseph Brant in Burlington, Trillium Health Partners in Mississauga and Owen Sound Hospital in Owen Sound. 

Air Liquide provided the entire liquid oxygen supply system consisting of bulk tanks, vaporizers, regulating stations, concrete and steel pads at the three facilities. Additionally Air Liquide will supply medical liquid oxygen to support the hospital ongoing needs during this pandemic.

All three hospitals are building step-down centers for lower-criticality COVID-19 patients, both to isolate these patients outside the hospital and to free up beds in intensive care units within the main hospitals. Each of the centers is temporary and has the capacity to assess and provide care for approximately 80 patients at any one time.

The Joseph Brant Hospital and the Trillium Health Mississauga hospitals are located on the hospitals' respective parking lots, while Owen Sound opted to set up their temporary hospital in the local ice hockey arena to take advantage of the existing facility and avoid building a new structure. All are temporary solutions and will be dismantled after the pandemic passes.

Chris Mendonça, Vice President, Air Liquide Healthcare, Canada, said “We are committed to supporting our communities through this crisis. The quick transition of these facilities to temporary hospitals is in process and Air Liquide teams mobilized to ensure timely completion to aid in their commissioning. We are proud that as a business we can support such critical initiatives as supplying medical oxygen to those affected by COVID-19. It’s our employees’ collaboration with local hospitals and their unwavering dedication that have made this possible.”

A world leader in gases, technology and services for industry and health, Air Liquide is in a unique position to help combat this pandemic. With vital operations in both the supply of medical gases, and in critical health and safety equipment and hardgoods, continuity of business and maintaining the health and well-being of our customers, patients and employees remains essential. As this situation evolves in both Canada and globally, Air Liquide stands ready and committed to reliably serve its customers, patients and partners during this time of uncertainty. 

Air Liquide in Canada
Air Liquide started its activity in Canada in 1911 and now has a team of more than 2,500 employees working to serve more than 200,000 customers and patients across Canada. In all of the country’s key industrial regions from coast to coast, Air Liquide offers innovative solutions — gas, equipment and services — in a wide variety of sectors: healthcare, aeronautics, automotive, agri-food industries, chemical, metallurgy, metal fabrication, mining and oil and gas.

Air Liquide Healthcare
Supplies medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients. In 2019, it served over 15,000 hospitals and clinics and more than 1.7 million patients at home throughout the world. The Group’s Healthcare business reached €3,693 million in revenues in 2019, with the support of its 16,500 employees.

CONTACTS

Corporate Communications
media@airliquide.com

Investor Relations
IRTeam@airliquide.com

Communications - Canada
joan.beauchamp@airliquide.com
514 258-7194

A world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 67,000 employees and serves more than 3.7 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide’s scientific territory and have been at the core of the company’s activities since its creation in 1902.

Air Liquide’s ambition is to be a leader in its industry, deliver long term performance and contribute to sustainability. The company’s customer-centric transformation strategy aims at profitable, regular and responsible growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.

Air Liquide’s revenue amounted to 22 billion euros in 2019 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.